Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia

Acta Anaesthesiol Scand. 1997 Mar;41(3):422-6. doi: 10.1111/j.1399-6576.1997.tb04709.x.

Abstract

N-methyl-D-aspartate (NMDA) receptors are involved in the development of neuropathic pain. Ketamine, a non-competitive NMDA receptor antagonist, has in several case reports given pain relief but efficacy in dosages tolerated in long-term ketamine treatment is unknown. Another substance with an antagonist action at NMDA receptors and which is approved for peroral administration is dextromethorphan. In a randomized study dextromethorphan was no better than placebo for neuropathic pain but this does not exclude efficacy in selected patients. We report a patient with severe post-herpetic pain resistant to conventional pain treatment which was treated with ketamine for 4 years with good pain relief. The practical application of long-term treatment in different administration forms of ketamine is described. The patient also responded with pain relief in a double-blind trial with oral dextromethorphan.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Dextromethorphan / administration & dosage*
  • Excitatory Amino Acid Antagonists / administration & dosage*
  • Excitatory Amino Acid Antagonists / adverse effects
  • Herpes Zoster / complications*
  • Humans
  • Ketamine / administration & dosage*
  • Ketamine / adverse effects
  • Male
  • Neuralgia / drug therapy*
  • Neuralgia / etiology
  • Pain Measurement
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
  • Time Factors

Substances

  • Excitatory Amino Acid Antagonists
  • Receptors, N-Methyl-D-Aspartate
  • Ketamine
  • Dextromethorphan